

Marek Z Wojtukiewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6034661/publications.pdf>

Version: 2024-02-01

122
papers

5,048
citations

126708

33
h-index

95083

68
g-index

127
all docs

127
docs citations

127
times ranked

6167
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
2	First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 1178-1184.	0.8	444
3	Platelets and Angiogenesis in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 95-108.	1.5	282
4	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	0.6	247
5	Platelets and cancer angiogenesis nexus. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 249-262.	2.7	172
6	Pathways of Coagulation/Fibrinolysis Activation in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 1992, 18, 104-116.	1.5	168
7	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	5.1	125
8	Thrombin increases the metastatic potential of tumor cells. <i>International Journal of Cancer</i> , 1993, 54, 793-806.	2.3	109
9	Protease-activated receptors (PARs)â€”biology and role in cancer invasion and metastasis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 775-796.	2.7	109
10	The Hemostatic System and Angiogenesis in Malignancy. <i>Neoplasia</i> , 2001, 3, 371-384.	2.3	108
11	Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 712-721.	1.5	108
12	Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1055-1062.	5.1	101
13	The Role of Tissue Factor Pathway Inhibitor-2 in Cancer Biology. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 653-659.	1.5	86
14	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€”Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 968-974.	0.8	78
15	Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. <i>Cancer</i> , 1990, 65, 481-485.	2.0	72
16	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
17	Thrombin enhances tumor cell adhesive and metastatic properties via increased Î±IIbÎ²3 expression on the cell surface. <i>Thrombosis Research</i> , 1992, 68, 233-245.	0.8	71
18	Thrombinâ€”unique coagulation system protein with multifaceted impacts on cancer and metastasis. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 213-233.	2.7	68

#	ARTICLE	IF	CITATIONS
19	Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5) Tj ETQq1 1 0.784314 rgBT /Overleed Annals of Oncology, 2009, 20, 1794-1802.	0.6	63
20	Enhanced prolidase activity and decreased collagen content in breast cancer tissue. International Journal of Experimental Pathology, 2006, 87, 289-296.	0.6	60
21	Contribution of the Hemostatic System to Angiogenesis in Cancer. Seminars in Thrombosis and Hemostasis, 2004, 30, 5-20.	1.5	59
22	Malignant Melanoma: Interaction with Coagulation and Fibrinolysis Pathways In Situ. American Journal of Clinical Pathology, 1990, 93, 516-521.	0.4	58
23	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. European Journal of Cancer, 2018, 93, 19-27.	1.3	58
24	Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagulation and Fibrinolysis, 1992, 3, 429-437.	0.5	57
25	Cancer epidemiology in Central and South Eastern European countries. Croatian Medical Journal, 2011, 52, 478-487.	0.2	53
26	Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer, 2006, 95, 788-793.	2.9	52
27	Tissue Factor-Dependent Coagulation Activation and Impaired Fibrinolysis in Situ in Gastric Cancer. Seminars in Thrombosis and Hemostasis, 2003, 29, 291-300.	1.5	49
28	Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?. Cancer and Metastasis Reviews, 2017, 36, 305-329.	2.7	46
29	Indirect Activation of Blood Coagulation in Colon Cancer. Thrombosis and Haemostasis, 1989, 62, 1062-1066.	1.8	46
30	Localization of Blood Coagulation Factors In Situ in Pancreatic Carcinoma. Thrombosis and Haemostasis, 2001, 86, 1416-1420.	1.8	42
31	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis, 2003, 90, 140-146.	1.8	41
32	Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thrombosis and Haemostasis, 2010, 103, 198-204.	1.8	41
33	Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer, 1991, 67, 1377-1383.	2.0	40
34	Cathepsin A activity in primary and metastatic human melanocytic tumors. Archives of Dermatological Research, 2000, 292, 68-71.	1.1	34
35	Expression of Prothrombin Fragment 1+2 in Cancer Tissue as an Indicator of Local Activation of Blood Coagulation. Thrombosis Research, 2000, 97, 335-342.	0.8	33
36	PET/MRI-guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlentherapie Und Onkologie, 2019, 195, 780-791.	1.0	33

#	ARTICLE	IF	CITATIONS
37	Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in situ in Laryngeal Carcinoma. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1659-1662.	1.8	28
38	Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. <i>Thrombosis Research</i> , 1988, 51, 575-581.	0.8	27
39	The Role of Hemostatic System Inhibitors in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 621-642.	1.5	27
40	Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: Implications for coagulation regulation on tumor cells. <i>Thrombosis Research</i> , 2012, 129, e112-e118.	0.8	25
41	Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. <i>Thrombosis and Haemostasis</i> , 2004, 92, 171-177.	1.8	24
42	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. <i>Bone Marrow Transplantation</i> , 2004, 33, 1225-1229.	1.3	24
43	Plasma Factor XIII and some other Haemostasis Parameters in Patients with Diabetic Angiopathy. <i>Acta Haematologica</i> , 1986, 76, 81-85.	0.7	23
44	The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. <i>Clinica Chimica Acta</i> , 2006, 371, 112-116.	0.5	23
45	Lactacystin Inhibits Cathepsin A Activity in Melanoma Cell Lines. <i>Tumor Biology</i> , 2001, 22, 211-215.	0.8	22
46	Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. <i>Thrombosis Research</i> , 1989, 55, 279-284.	0.8	21
47	Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. <i>Thrombosis and Haemostasis</i> , 2003, 90, 140-6.	1.8	21
48	Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination. <i>Cancers</i> , 2019, 11, 51.	1.7	20
49	Increased serum level of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) in patients with breast cancer.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 48, 101-3.	0.6	20
50	Cancer procoagulant in patients with adenocarcinomas. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 543-547.	0.5	19
51	Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm. <i>Cancers</i> , 2020, 12, 1144.	1.7	18
52	Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. <i>Thrombosis Research</i> , 2010, 125, e71-e75.	0.8	17
53	Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience. <i>International Dental Journal</i> , 2015, 65, 242-248.	1.0	17
54	Personalized Radiation Therapy in Cancer Pain Management. <i>Cancers</i> , 2019, 11, 390.	1.7	17

#	ARTICLE	IF	CITATIONS
55	Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. <i>Advances in Medical Sciences</i> , 2013, 58, 207-215.	0.9	16
56	XYY syndrome and acute myeloblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1987, 24, 363-365.	1.0	15
57	Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. <i>Thrombosis and Haemostasis</i> , 2010, 104, 183-185.	1.8	15
58	Protein Z is present in human breast cancer tissue. <i>International Journal of Hematology</i> , 2011, 93, 681-683.	0.7	15
59	Von Willebrand factor antigen and fibronectin in essential hypertension. <i>Thrombosis Research</i> , 1995, 79, 331-336.	0.8	14
60	Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue. <i>Thrombosis Research</i> , 2012, 129, e92-e96.	0.8	14
61	Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions. <i>Cells</i> , 2021, 10, 2044.	1.8	14
62	Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer. <i>Annals of Hematology</i> , 2014, 93, 779-784.	0.8	13
63	Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy. <i>Pathology and Oncology Research</i> , 2020, 26, 2499-2507.	0.9	13
64	Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues.. <i>Blood</i> , 2004, 104, 3958-3958.	0.6	13
65	Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. <i>Tumor Biology</i> , 2011, 32, 753-759.	0.8	11
66	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. <i>Wspolczesna Onkologia</i> , 2013, 3, 257-262.	0.7	11
67	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	0.8	11
68	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	0.8	11
69	Platelet activation and its role in thrombin generation in platelet-induced thrombin generation time. <i>Thrombosis Research</i> , 2000, 100, 419-426.	0.8	10
70	It is not just the drugs that matter: the nocebo effect. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 315-326.	2.7	10
71	Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 505-511.	0.6	10
72	Coagulation activators and inhibitors in the neointima of polyester vascular grafts. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 433-439.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. <i>Onkologie</i> , 2011, 34, 233-238.	1.1	8
74	Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. <i>Biomolecules</i> , 2021, 11, 663.	1.8	8
75	Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1. <i>Cancer Research</i> , 2015, 75, P5-19-01-P5-19-01.	0.4	8
76	Occurrence of Components of Fibrinolytic Pathways in Situ in Laryngeal Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 317-320.	1.5	7
77	7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC). <i>European Journal of Cancer</i> , 2011, 47, S517.	1.3	7
78	Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (>20%) FN-risk chemotherapy: results from a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 1449-1457.	1.0	7
79	Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?. <i>Wspolczesna Onkologia</i> , 2016, 2, 102-108.	0.7	6
80	Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. <i>In Vivo</i> , 2019, 33, 771-776.	0.6	6
81	TFPI (Tissue Factor Pathway Inhibitor) Is Present in Breast Cancer Tumor Cells. <i>Blood</i> , 2006, 108, 4035-4035.	0.6	6
82	Interfering with Hemostatic System Components: Possible New Approaches to Antiangiogenic Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 145-156.	1.5	5
83	Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts. <i>Biomaterials</i> , 2004, 25, 5987-5993.	5.7	5
84	Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 455-457.	0.4	5
85	Protease-activated receptors " biology and role in cancer. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 775-786.	0.1	5
86	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011, 31, 843-7.	0.5	5
87	Thromboprophylaxis in cancer patients in hospice. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 283-289.	0.6	4
88	Massive saddle pulmonary embolism during radiochemotherapy of head and neck cancer. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 561-563.	0.3	4
89	Ozonation of Whole Blood Results in an Increased Release of Microparticles from Blood Cells. <i>Biomolecules</i> , 2022, 12, 164.	1.8	4
90	Platelet-Induced Thrombin Generation Time II (PITT II) A Modified Global Coagulation Test to Monitor Prophylactic Anticoagulation with Vitamin K Antagonists?. <i>Thrombosis Research</i> , 1999, 96, 77-81.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC). <i>European Journal of Cancer</i> , 1999, 35, S317.	1.3	3
92	Endothelial Microparticles and Blood Coagulation Activation in Head and Neck Cancer Patients Undergoing Radiotherapy or Radiochemotherapy. <i>In Vivo</i> , 2019, 33, 627-632.	0.6	3
93	Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade. <i>Pathology and Oncology Research</i> , 2021, 27, 605017.	0.9	3
94	Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells. <i>Journal of BU on</i> , 2015, 20, 1426-31.	0.4	3
95	PO-28 Expression of tissue factor (TF), tissue factor pathway inhibitor (TFPI), factor IX and factor X in breast cancer: comparison between primary tumor and metastatic lesions in regional lymph nodes. <i>Thrombosis Research</i> , 2007, 120, S154.	0.8	2
96	The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. <i>International Journal of Hematology</i> , 2009, 89, 276-284.	0.7	2
97	Psychological, Physical, and Social Situation of Polish Patients With Colorectal Cancer Undergoing First-Line Palliative Chemotherapy. <i>Oncology Nursing Forum</i> , 2011, 38, E253-E259.	0.5	2
98	Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project. <i>Wspolczesna Onkologia</i> , 2014, 6, 425-428.	0.7	2
99	Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 1185-1192.	0.6	2
100	Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients. <i>Nowotwory</i> , 2016, 66, 326-350.	0.1	2
101	Polish Consensus on Treatment of Gastric Cancer; update 2017. <i>Polski Przegląd Chirurgiczny</i> , 2017, 89, 59-73.	0.2	2
102	Decreased plasma protein C levels after high dosage of acetylsalicylic acid. <i>Thrombosis Research</i> , 1993, 69, 401-406.	0.8	1
103	The Effects of Polysulfonate Derivative (GL 2021) on Coagulation in Vitro and Thrombosis in Vivo. <i>Thrombosis Research</i> , 2000, 99, 99-104.	0.8	1
104	Inhibitors of Hemostatic System in Cancer: Basic and Clinical Aspects. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 619-620.	1.5	1
105	Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment*. , 2012, , .		1
106	Expression of Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Different Malignant Tumors.. <i>Blood</i> , 2004, 104, 3959-3959.	0.6	1
107	Heterogeneous Expression of Protein C (PC), Protein S (PS) and Thrombomodulin (TM) in Human Colon Cancer Tissue.. <i>Blood</i> , 2006, 108, 4037-4037.	0.6	1
108	Hippocampal sparing in brain radiotherapy. <i>Nowotwory</i> , 2016, 66, 299-306.	0.1	1

#	ARTICLE	IF	CITATIONS
109	Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, e12631-e12631.	0.8	1
110	Protein c and protein S in patients with peripheral arterial occlusive disease. Thrombosis Research, 1993, 70, 489-492.	0.8	0
111	Evaluation of Urokinase-Type Plasminogen Activator and Its Receptor in Neointima of Polyester Vascular Crafts. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 23-28.	0.5	0
112	882 poster 3-YEAR OVERALL SURVIVAL FOR INOPERABLE NON-SMALL CELL LUNG CARCINOMA PATIENTS TREATED WITH RA-DIOCHEMOTHERAPY " SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.. Radiotherapy and Oncology, 2011, 99, S340.	0.3	0
113	924 poster ADIUVANT RADIOCHEMOTHERAPY FOR GASTRIC CANCER PATIENTS " SINGLE-INSTITUTION RETROSPECTIVE EXPERIENCE.. Radiotherapy and Oncology, 2011, 99, S355.	0.3	0
114	Testicular Doses in Image Guided Step-and-Shoot Intensity Modulated Radiation Therapy of Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2013, 87, S377.	0.4	0
115	Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. Wspolczesna Onkologia, 2014, 6, 419-424.	0.7	0
116	Testicular Dose Contributed by Image-Guided Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2014, 90, S426.	0.4	0
117	EP-1179: Usefulness of [18F]FDG-PET/MRI in clinical evaluation of head and neck cancer (HNC) patients (pts). Radiotherapy and Oncology, 2018, 127, S660-S661.	0.3	0
118	Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy. In Vivo, 2019, 33, 581-586.	0.6	0
119	Comparative Analysis of Coagulation System Proteins Distribution in Breast Cancer Primary Lesions and Lymph Node Metastases.. Blood, 2007, 110, 3137-3137.	0.6	0
120	Wszczepialne systemy dostÄ™pu naczyniowego u chorych na nowotwory. Nowotwory, 2015, 65, 302-316.	0.1	0
121	Wyniki leczenia wemurafenibem chorych na zaawansowanego czerniaka w ramach programu lekowego w Polsce. Nowotwory, 2016, 66, 118-126.	0.1	0
122	Is AIO belly board device advantageous in all rectal cancer patients. Nowotwory, 2018, 67, 342-348.	0.1	0